Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Zymeworks Inc ZYME

Healthcare Biotechnology
Zymeworks Inc. is a global biotechnology company. The Company is engaged in the discovery, development, and commercialization of multifunctional biotherapeutics to treat cancer and other serious diseases. Its complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop differentiated antibody-based... see more

Recent & Breaking News (NDAQ:ZYME)

Zymeworks Announces Updated Clinical Data for Novel Bispecific Antibody, ZW25, Presented at the EORTC-NCI-AACR Symposium

Business Wire November 14, 2018

Recent Analysis Shows Cleveland-Cliffs, Optical Cable, Camtek, QIAGEN N.V, Value Line, and Zymeworks Market Influences — Renewed Outlook, Key Drivers of Growth

GlobeNewswire November 13, 2018

Zymeworks to Present at Upcoming Investor Conferences

Business Wire November 7, 2018

Zymeworks Reports Financial Results for the Third Quarter of 2018

Business Wire November 6, 2018

Zymeworks Announces Selection of ZW25 Abstract for Plenary Session Presentation at the 30th EORTC-NCI-AACR Symposium

Business Wire October 30, 2018

Zymeworks and LEO Pharma Enter into Bispecific Antibody Licensing and Research Collaboration

Business Wire October 23, 2018

Zymeworks to Webcast R&D Briefing

Business Wire October 4, 2018

Zymeworks to Present at Ladenburg Thalmann 2018 Healthcare Conference

Business Wire September 25, 2018

Zymeworks Names Anthony Polverino, Ph.D., Executive Vice President of Early Development and Chief Scientific Officer

Business Wire September 19, 2018

Zymeworks Reports IND-Submission Milestone Achieved in Lilly Collaboration

Business Wire September 4, 2018

Zymeworks to Present at Wells Fargo Healthcare Conference

Business Wire August 29, 2018

Zymeworks to Present at Canaccord Genuity 38th Annual Growth Conference

Business Wire August 2, 2018

Zymeworks Reports Financial Results for the Second Quarter of 2018

Business Wire August 1, 2018

Zymeworks Closes Previously Announced Public Offering

Business Wire June 11, 2018

Zymeworks Announces Election of Directors and Voting Results from Shareholder Meeting

Business Wire June 7, 2018

IIROC Trade Resumption - SMU.UN; PL; ZYME; APH; NVU.UN

Canada NewsWire June 7, 2018

Zymeworks Announces Pricing of Public Offering

Business Wire June 6, 2018

IIROC Trading Halt - ZYME

Canada NewsWire June 6, 2018

Zymeworks Files Preliminary Prospectus Supplement for Offering of Common Shares

Business Wire June 6, 2018

IIROC Trade Resumption - ZYME

Canada NewsWire June 1, 2018